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Background: The cytotoxic effects of microtubule-targeting agents (MTAs) are often attributed
to targeted effects on mitotic cells. In clinical practice, MTAs are combined with DNA-damaging
agents such as ionizing radiation (IR) with the rationale that mitotic cells are highly sensitive to
DNA damage. In contrast, recent studies suggest that MTAs synergize with IR by interfering
with the trafficking of DNA damage response (DDR) proteins during interphase. These studies,
however, have yet to demonstrate the functional consequences of interfering with interphase
microtubules in the presence of IR. To address this, we combined IR with an established MTA,
mebendazole (MBZ), to treat glioma cells exclusively during interphase.
Materials and methods: To test whether MTAs can sensitize interphase cells to IR, we
treated GL261 and GBM14 glioma cells with MBZ during 3–9 hours post IR (when the mitotic
index was 0%). Cell viability was measured using a WST-1 assay, and radiosensitization was
quantified using the dose enhancement factor (DEF). The effect of MBZ on the DDR was
studied via Western blot analysis of H2AX phosphorylation. To examine the effects of MTAs on
intracellular transport of DDR proteins, Nbs1 and Chk2, cytoplasmic and nuclear fractionation
studies were conducted following treatment of glioma cells with MBZ.
Results: Treatment with MBZ sensitized interphase cells to the effects of IR, with a maximal
DEF of 1.34 in GL261 cells and 1.69 in GBM14 cells. Treatment of interphase cells with MBZ
led to more sustained γH2AX levels post IR, indicating a delay in the DDR. Exposure of glioma
cells to MBZ resulted in a dose-dependent sequestration of Chk2 and Nbs1 in the cytoplasm.
Conclusion: This study demonstrates that MBZ can sensitize cancer cells to IR independently
of the induction of mitotic arrest. In addition, evidence is provided supporting the hypothesis
that MTA-induced radiosensitization is mediated by inhibiting DDR protein accumulation into
the nucleus.
Keywords: microtubules, mebendazole, ionizing radiation, radiosensitization, interphase,
DNA damage response
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Microtubule-targeting agents (MTAs) have been used for a long time against a wide
range of malignancies. It is generally believed that MTAs kill cancer cells by causing
cell cycle arrest in M-phase, followed by activation of apoptotic pathways and cell
death.1–4 Many studies have used this rationale to explain the potent radiosensitization
effects exerted by MTAs,5,6 ie, by inducing mitotic arrest, MTAs increase the proportion
of tumor cells in a phase of the cell cycle that is very susceptible to DNA damage.7,8
Currently, chemoradiotherapy regimens including MTAs have been proven effective for
the treatment of breast cancer, esophageal cancer and a variety of other neoplasms.9,10
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Support for a mitosis-based mechanism for the therapeutic effects of MTAs has been derived from the characteristic
side effects of these drugs, which include hair loss, neutropenia and gastrointestinal upset. These deleterious effects
demonstrate the profound sensitivity of rapidly dividing
tissues to MTAs. However, the action of MTAs on mitotic
cells fails to explain their clinical efficacy against many
slow-growing solid tumors with exceptionally low mitotic
indices.11 Most human tumors have a doubling time of
30–60 days or longer, making it unlikely that mitotic arrest
serves as a critical mechanism of MTA-induced therapeutic
benefit.12 A prime example of this “proliferation rate paradox”
is the significant activity of MTAs against adenocarcinoma
of the prostate, a highly indolent cancer.13,14 Thus, a number
of interphase-based mechanisms for the efficacy of MTAs
in cancer therapy have been proposed, although not without
controversy.15,16
A recent study has shown that the MTAs, vincristine
(VCR) and paclitaxel, can delay DNA damage repair.17 These
MTAs were also shown to interfere with the trafficking of
DNA damage response (DDR) proteins, including ATM,
ATR and p53, from the cytosol to the nucleus, strongly
suggesting that MTAs can sensitize cells to radiation by
blocking microtubule-based transport of DDR proteins into
the nucleus during interphase.
It is challenging to physically separate mitotic from interphase cells in the presence of an MTA, as this results in a
steady accumulation of new mitotic cells as long as the MTA
is present. Thus, the question remains as to what extent the
role of MTAs in radiosensitization is caused by interference
with microtubule-facilitated nuclear import. To address this
question, we took advantage of the fact that ionizing radiation
(IR) treatment induces G2–M cell cycle arrest, thereby transiently eliminating the mitotic cell population and strongly
enriching for interphase cells. Using glioblastoma cells and
the MTA, mebendazole (MBZ), as a model system, we show
that the effect of MBZ in interphase is responsible for the
majority of the radiosensitization effect of this MTA.

and cultured in StemPro media (Thermo Fisher Scientific),
as directed by the manufacturer.

Materials and methods
Cell lines and reagents

Cell viability assays

GL261 (glioma) cells were obtained from the National
Cancer Institute (Frederick, MD, USA). Cells were cultured
in macrophage serum-free medium (Thermo Fisher Scientific,
Waltham, MA, USA) containing 10% fetal bovine serum, 1%
penicillin/streptomycin and 1 mM l-glutamine. GBM14 cells
have been described previously,18 and they were obtained
by Dr J Sarkaria at Mayo Clinic (Rochester, MN, USA)
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Drug treatment
For each experiment, GL261 and GBM14 cells were cultured
without drug or treated with MBZ (Sigma-Aldrich Co.,
St Louis, MO, USA). MBZ stocks were prepared by dissolving
the drug in dimethyl sulfoxide (DMSO; Sigma-Aldrich Co.).
About 24 hours after plating, glioma cells were treated with
MBZ, while control cells were treated with 0.01% DMSO.

Irradiation procedure
For all experiments requiring radiation, cells were irradiated
using a biological irradiator (RS2000; Rad Source Technologies, Buford, GA, USA).

Antibodies
Phospho-MPM2 was obtained from EMD Millipore (Billerica,
MA, USA), and γH2AX, H2AX, Chk2, Nbs1 and GAPDH
were purchased from Cell Signaling (Danvers, MA, USA).

Immunofluorescence
GL261 cells were seeded at a density of 30,000 cells/well
in 24-well plates containing cover slips coated with laminin
(Sigma-Aldrich Co.). The following day, cells were exposed
to 6 Gy of IR. At designated time points post IR, cells were
washed in PBS and fixed in 4% formaldehyde in PBS at room
temperature. Once the cells were fixed, immunofluorescence
was performed using an MPM2 antibody (EMD Millipore)
and counterstained with 4,6-Diamidino-2-phenylindole,
dihydrochloride (DAPI). For each condition, a total of 10
fluorescence micrograph images were taken with a Zeiss
Axiovert 200M inverted microscope (Thornwood, NY, USA),
running on Axiovision software. For each image field, the
total number of cells and the number of MPM2-positive cells
were quantified. The mitotic index was calculated at each time
point using the number of MPM2-positive cells as a percentage of the total number of cells counted in all 10 fields.

GL261 cells were seeded in 96-well plates at a density of
1,000 cells/well. GBM14 cells were seeded at a density of
10,000 cells/well. About 24 hours after seeding, cells were
treated with 25–150 nM MBZ and irradiated with 3, 6 or 9 Gy.
Drug treatment was applied for a 6-hour time window beginning either 6 hours pre IR or 3 hours post IR. Following the
6-hour window, the drug was washed out and replaced with
fresh medium. Control cells were either left nonirradiated or
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irradiated with 3, 6 or 9 Gy of IR. Cell viability was examined
72 hours post IR using a WST-1 cell viability assay (Abcam,
Cambridge, MA, USA) at an absorbance of 450 nm. For any
given radiation dose–response, data were normalized by the
fraction of viable cells treated with a given dose of drug
in the absence of radiation. The radiosensitizing effect of
MBZ and VCR was quantified using the dose enhancement
factor (DEF) at the point of 50% (DEF50) cell viability. The
DEF was calculated for each MBZ concentration using the
following formula: (surviving fraction with radiation alone)/
(surviving fraction with radiation + MBZ).

Assessment of the DDR
GL261 cells were seeded at a density of 800,000 cells/well
in 6-cm dishes. About 24 hours after seeding, cells were
irradiated with 6 Gy of IR, followed by treatment with
150 nM MBZ during 3–9 hours post IR. Control cells were
either left nonirradiated or irradiated with 6 Gy. All cells
were harvested in lysis buffer at 0.5, 3, 6 and 9 hours post
IR. The lysis buffer was composed of 50 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% Nonidet P-40,
1× protease inhibitor (Thermo Fisher Scientific), phosphatase
inhibitor (Hoffman-La Roche Ltd., Basel, Switzerland) and
0.4 U/mL Benzonase (EMD Millipore). For each condition,
60 µg of cell lysate was diluted in 1× NuPAGE Sample
Reducing Agent (Thermo Fisher Scientific) and 1× NuPAGE
LDS Sample Buffer (Thermo Fisher Scientific). All samples
were loaded onto a NuPAGE, 4%–12% Bis-Tris Protein Gel
(Thermo Fisher Scientific) for Western blot analysis. Histone
H2AX and γH2AX were detected by Western blot using
anti-histone H2AX or anti-γ-H2AX (Ser139) monoclonal
antibodies (Cell Signaling).

Nuclear and cytoplasmic fractionation
GL261 cells were seeded at a density of 500,000 cells in
6-cm dishes. The following day, cells were treated with 3 Gy.
MBZ treatment (25–250 nM) was performed for a 6-hour
time window beginning 3 hours post IR. Irradiated control
cells were treated with 3 Gy followed by 0.01% DMSO in
medium during the same time period. Nonirradiated control
cells were treated with 0.01% DMSO in medium for a total
of 6 hours. After the 6-hour period of MBZ treatment, cells
were harvested for protein analysis in cytoplasmic (C) and
nuclear (N) fractions. The C and N fractions were collected
according to the protocol of the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Fisher Scientific).
For each sample, 20% of the final volume of the C or N fractions was diluted in 1× NuPAGE Sample Reducing Agent
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Table 1 DEF50 for MBZ-mediated radiosensitization, cytoplasmic
sequestration of DDR proteins and induction of mitotic arrest
Treatment

EC50 (nM)

95% CI

Radiosensitization (DEF50)
Nuclear trafficking (Chk2)
Nuclear trafficking (Nbs1)
Mitotic arrest

35
31
25
192*

9–50
17–45
18–32
127–257

Notes: Each EC50 value represents the average of three independent experiments
with the representative 95% CI. DEFs were determined from WST assays conducted
in GL261 cells with MBZ treatment during the period of 3–9 hours post IR. The EC50
of radiosensitization is defined by the half-maximal DEF at 50% cell viability (DEF50).
Data used to determine the EC50 for induction of mitotic arrest by MBZ were
obtained previously, also using GL261 cells.23 *P,0.01.
Abbreviations: CI, confidence interval; DDR, DNA damage response; DEF, dose
enhancement factor; EC50, concentration of a drug that gives half-maximal response;
IR, ionizing radiation; MBZ, mebendazole.

and 1× NuPAGE LDS Sample Buffer. All samples were
loaded onto a NuPAGE, 4%–12% Bis-Tris Protein Gel for
Western blot analysis. Blots were incubated in antibodies:
Nbs1, Chk2, GAPDH and H2AX monoclonal antibodies (all
from Cell signaling). Cytoplasmic and nuclear fractions were
normalized by GAPDH and H2AX levels, respectively. The
percentage of cytoplasmic retention of DDR proteins was
calculated by the following formula: [C/(C + N)] × 100%.

Statistical analysis
All analyses were performed using Graphpad Prism 7
software. Radiosensitization experiments were analyzed
using the two-way ANOVA method to compare the mean
cell viability between treatment groups. The interaction
between the MBZ treatment group and radiation dose was
also examined. One-way ANOVA was used to compare the
concentration of a drug that gives half-maximal response
(EC50) values for each effect as outlined in Table 1. If a significant difference between means was found by ANOVA,
then multiple comparisons between treatment groups were
conducted. The Tukey–Kramer method was used to adjust for
multiple comparisons. Studies examining the effect of MBZ
on intracellular transport of DDR proteins were analyzed with
unpaired two-tailed Student’s t-test for direct comparisons
of means. The same method was used to compare means in
the analysis of H2AX phosphorylation following exposure
to IR. For all studies, results were considered statistically
significant for values of P,0.05.

Results
IR transiently eliminates the mitotic
cell population
To select for a population composed entirely of interphase
cells, we took advantage of the fact that IR treatment induces
G2–M cell cycle arrest and transiently eliminates the mitotic
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cell population. Glioma cells were treated with 6 Gy of IR.
To monitor the mitotic index, we quantified the proportion
of MPM2-positive cells by immunofluorescence at several
time points post IR. MPM2 is an antibody that recognizes
a phosphorylated serine/threonine epitope found in proteins
that are phosphorylated at the onset of mitosis.19 MPM2 is
recognized as a reliable mitotic marker in the literature and
has been used to assess the mitotic index in cells exposed to
radiation and a number of chemotherapeutic agents.20–22 The
baseline mitotic index of the glioma cell population was 3.5%
and was strongly inhibited during a period of 3–10 hours
after exposure to 6 Gy of IR. Recovery of the mitotic cell
population begins after 10 hours post IR and completes by
24 hours post IR. To confirm that the mitotic index remained
strongly inhibited even in the presence of MBZ, we applied
MBZ during 3–9 hours post IR. In the presence of MBZ,
the mitotic index remained suppressed at 4 hours (mitotic
index =0.58%), 6 hours (mitotic index =0.12%) and 9 hours
(mitotic index =0.28%) post IR. Thus, the treatment of GL261
glioma cells with 6 Gy of IR eliminated the mitotic cell population for a time period of ~6 hours (Figure 1).

MTAs sensitize interphase cells to IR
In the following experiments, we compared the radiosensitizing effect of MTAs when applied during different time periods
with respect to IR, using both murine GL261 cells and primary
patient-derived GBM14 cells. A simplified schematic of all
three treatment conditions is shown in Figure 2. To examine
whether MTAs can sensitize glioma cells to IR, we treated
GL261 cells with MBZ (Figures 3 and 4) or VCR (Figure 5).
In order to test, whether MTAs can sensitize interphase cells
to IR, we treated glioma cells with 25–150 nM MBZ during
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Figure 1 IR temporarily eliminates the mitotic cell population.
Notes: GL261 cells were exposed to 6 Gy of IR, and the proportion of MPM2positive cells was quantified by immunofluorescence as described in the
“Immunofluorescence” section. MPM2 was utilized as a marker of the mitotic index.
Data are expressed as the average ± SEM of three independent experiments.
Abbreviations: IR, ionizing radiation; SEM, standard error of the mean.
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Figure 2 Timing of MBZ application with respect to IR.
Notes: (A) MBZ was applied for a 6-hour time frame beginning 6 hours pre IR
followed by washout of the drug. During this time period, both mitotic and interphase
cells were present. (B) MBZ was applied for a 6-hour time frame beginning 3 hours
post IR followed by washout of the drug. During this time period, the mitotic cell
population was absent (composed entirely of interphase cells). (C) MBZ was applied
beginning 6 hour pre IR and left in the medium for the duration of the experiment.
Abbreviations: IR, ionizing radiation; MBZ, mebendazole.

3–9 hours post IR (Figures 3A and 4A). The use of MBZ
after exposure to IR made it possible to study the impact of
MBZ independent of its effect on mitotic cells. Cells were
exposed to MBZ after different doses of IR. After this 6-hour
time frame, the drug was washed out and replaced with a
drug-free medium. The radiosensitizing effect of MBZ on
interphase cells was compared with the effect of MBZ on a
cell population composed of both interphase and mitotic cells.
Thus, cells were treated with MBZ for a 6-hour time window
immediately prior to irradiation, and subsequently the drug
was either washed out and replaced with drug-free medium
(Figures 3B and 4B) or left in the original medium until the end
of the assay, 72 hours post IR (Figures 3C and 4C). Treatment
with MBZ post IR sensitized GL261 cells to IR with a maximal
DEF at 50% viability (DEF50) of 1.34 (Figure 3D). Treatment
for a 6-hour time window pre IR, which increased the mitotic
index to 9.2% from a baseline value of 2.8%,23 sensitized
glioma cells to IR with a maximal DEF50 of 1.2 in GL261
cells (Figure 3E) and 1.33 in GBM14 cells (Figure 4E). In the
GL261 cell line, maximal radiosensitization was observed
when the drug was applied pre IR and left in the medium for
72 hours, DEF50 =1.41 (Figure 3F). In the GBM14 cell line, the
application of the drug pre IR followed by 72-hour incubation
sensitized cells to IR with a DEF50 =1.60 (Figure 4F). Maximal
radiosensitization in the GBM14 cell line was achieved when
MBZ was applied post IR, DEF50 =1.69 (Figure 4D). These
observations show a maximal or near-maximal radiosensitization effect of MBZ when applied to cells during interphase.
To investigate whether these findings can be generalized
to other MTAs, we performed an identical set of experiments in GL261 cells using VCR, an established MTA that
is frequently used in clinical practice. The radiosensitizing
effect of VCR was greatest when applied post IR, DEF50 =1.53
(Figure 5A and D). The application of VCR for a 6-hour
OncoTargets and Therapy 2017:10
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Figure 3 MBZ sensitizes GL261 cells to IR.
Notes: GL261 cells were exposed to 25–150 nM of MBZ in conjunction with 3–9 Gy of IR. MBZ treatment was applied at different time points with respect to IR, and cell
viability was determined by the WST assay as described in the “Cell viability assays” section. All data are expressed as the average ± SEM of four independent experiments.
For each radiation dose–response curve, data were normalized by the fraction of viable cells treated with a given dose of MBZ in the absence of IR. DEFs were determined
at the point of 50% cell viability. (A) Cells were treated with MBZ during 3–9 hours post IR. (B) Cells were treated with MBZ for a 6-hour time window immediately prior
to irradiation. (C) Cells were treated with MBZ starting 6 hours prior to irradiation and until 72 hours post IR. P-values were ,0.05 for all treatments points when doses of
MBZ $50 nM. (D–F) The respective DEFs were calculated as described in the “Cell viability assays” section. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean.

period pre IR radiosensitized GL261 cells with a DEF50 of
1.34 (Figure 5B and E). When VCR was applied pre IR and
left in the medium for the remaining 72 hours, the magnitude
of the radiosensitizing effect was quite similar, DEF50 =1.30
(Figure 5C and F). Thus, it appears that the radiosensitizing
effect of both MBZ and VCR is largely determined by the
impact of these agents on interphase cells.
OncoTargets and Therapy 2017:10

MBZ treatment prolongs DDR after
irradiation
To confirm that MTAs sensitize interphase cells to IR by interfering with the DDR, we examined the level of IR-induced
phosphorylated H2AX (γH2AX), which is a highly sensitive
marker of DNA damage.24,25 We exposed glioma cells to
6 Gy of IR, followed by treatment with 150 nM MBZ during
submit your manuscript | www.dovepress.com
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Figure 4 MBZ sensitizes GBM14 cells to IR.
Notes: GBM14 cells were exposed to 50 or 150 nM of MBZ in conjunction with 3–9 Gy of IR. MBZ treatment was applied at different time points with respect to IR, and cell
viability was determined by the WST assay as described in the “Cell viability assays” section. All data are expressed as the average ± SEM of three independent experiments.
For each radiation dose–response curve, data were normalized by the fraction of viable cells treated with a given dose of MBZ in the absence of IR. DEFs were determined
at the point of 50% cell viability. (A) Cells were treated with MBZ during 3–9 hours post IR. (B) Cells were treated with MBZ for a 6-hour time window immediately prior
to irradiation. (C) Cells were treated with MBZ starting 6 hours prior to irradiation until 72 hours post IR. (D–F) The respective DEFs were calculated as described in the
“Cell viability assays” section. **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean.

3–9 hours post IR. Cells were harvested at different time
points post IR, and γH2AX was quantified by Western blot
analysis. As shown in Figure 6, treatment with MBZ led to
more sustained γH2AX levels in response to IR, indicating a delay in the DDR. This finding demonstrated that
MTAs sensitize interphase cells to IR by interfering with
the DDR.
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MBZ interferes with the trafficking of
DDR proteins
To investigate whether MTAs synergize with IR by disrupting intracellular transport of DDR proteins, we performed
cytoplasmic and nuclear (C/N) fractionation studies with
glioma cells that had been exposed to IR followed by treatment with MBZ. Similar to the cell viability studies, MBZ was
OncoTargets and Therapy 2017:10
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Figure 5 VCR sensitizes GL261 cells to IR.
Notes: GL261 cells were exposed to 0.5–2 nM of VCR in conjunction with 3–9 Gy of IR. Experiments with VCR were performed in an identical fashion to those with MBZ.
All data are expressed as the average ± SEM of three independent experiments. For each radiation dose–response curve, data were normalized by the fraction of viable cells
treated with a given dose of VCR in the absence of IR. DEFs were determined at the point of 50% cell viability. (A) Cells were treated with VCR during 3–9 hours post IR.
(B) Cells were treated with VCR for a 6-hour time window immediately prior to irradiation. (C) Cells were treated with VCR starting 6 hours prior to irradiation until
72 hours post IR. (D–F) The respective DEFs were calculated as described in the “Cell viability assays” section. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: DEF, dose enhancement factor; IR, ionizing radiation; MBZ, mebendazole; SEM, standard error of the mean; VCR, vincristine.

applied during 3–9 hours post IR (only when the mitotic cell
population was absent). Glioma cells were treated with different concentrations of MBZ followed by C/N fractionation.
Each fraction was analyzed by Western blot. We selected two
OncoTargets and Therapy 2017:10

DDR proteins, Chk2 and Nbs1, to serve as potential targets
of MTA-mediated toxicity. Chk2 is a key protein kinase
involved in the DDR that is responsible for cell cycle checkpoint activation and DNA repair following DNA damage
submit your manuscript | www.dovepress.com
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(Figure 7A). Radiation treatment did not significantly alter
the intracellular distribution of DDR proteins (Figure 7A).
Treatment of glioma cells with MBZ sequestered Chk2
and Nbs1 in the cytoplasm in a dose-dependent manner
(Figure 7B and C). These results demonstrate that MBZ, like
other MTAs,17 inhibits the trafficking of DDR proteins from
the cytoplasm to the nucleus.
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MBZ sensitizes glioma cells to IR by
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Figure 6 MBZ prolongs the DDR after exposure to IR.
Notes: (A) Western blot analysis. (B) Quantification of the Western blot bands.
GL261 cells were treated with 6 Gy of IR followed by treatment with 150 nM of
MBZ during 3–9 hours post IR. Control cells were treated only with IR. Following
treatment, cell lysates were harvested at different time points (0.5–9 hours) post IR
as described in the “Assessment of the DNA-damage response” section. Western
blot analysis of γH2AX and H2AX levels was conducted at each time point post IR,
and γH2AX levels were used as a measure of DNA damage. Data for each time point
are expressed as the average ± SEM of three independent experiments.
Abbreviations: DDR, DNA damage response; IR, ionizing radiation; MBZ,
mebendazole; SEM, standard error of the mean.

induced by IR.26 Nbs1 is a crucial component of an enzymatic
complex that repairs double strand breaks (DSBs) following
irradiation or heat shock.27
In control cells, which had not been treated with MBZ,
Chk2 and Nbs1 were localized entirely in the nucleus
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To more closely examine the relationship between the effects
of MBZ on intracellular trafficking of DDR proteins and IR
sensitization, we compared the EC50 values for radiosensitization (DEF), cytoplasmic sequestration of DDR proteins and
induction of mitotic arrest by MBZ (Table 1) in GL261 cells.
The EC50 was defined as the concentration of MBZ required
to achieve a half-maximal effect. The EC50 of cytoplasmic
sequestration for Chk2 (31 nM) and Nbs1 (25 nM) was
significantly lower than the EC50 of mitotic arrest (192 nM).
Most notably, the EC50 of radiosensitization (35 nM) was very
similar to the EC50 for cytoplasmic sequestration of DDR
proteins, but significantly lower than the EC50 of mitotic arrest
(P,0.01). Similarly, the EC50 for radiosensitization by VCR
(,0.5 nM) is significantly lower than the EC50 for mitotic
arrest in GL261 cells (2.5 nM).23 These findings support the
hypothesis that MBZ indeed radiosensitizes GL261 cells in
large part by interfering with intracellular trafficking of DDR
proteins during interphase.
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Figure 7 MBZ interferes with the trafficking of DDR proteins from the cytoplasm to the nucleus.
Notes: (A) GL261 cell were exposed to IR for 9 hours or left untreated. Cell lysates were collected using cytoplasmic and nuclear fractionation as described in the “Nuclear
and cytoplasmic fractionation” section. In untreated GL261 cells, DDR proteins are localized to the nucleus. Exposure to IR did not alter the intracellular distribution of
DDR proteins. (B) GL261 cells were exposed to IR followed by application of 25–250 nM of MBZ during 3–9 hours post IR. Western blot analysis of the cytoplasmic and
nuclear fractions was conducted, and the levels of DDR proteins, Chk2 and Nbs1, were quantified for each fraction. Exposure to MBZ post IR resulted in the dose-dependent
sequestration of DDR proteins in the cytoplasm. (C) The histogram shows quantification of Chk2 and Nbs1 levels from three independent experiments ± SE. *P,0.001.
Abbreviations: C, cytoplasmic; DDR, DNA damage response; IR, ionizing radiation; MBZ, mebendazole; N, nuclear; SE, standard error.
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Discussion
Studying the mechanisms of action of MTAs in cell toxicity,
and in particular whether MTAs target cells in mitotic
phase or interphase, has been hampered by the difficulty in
separating these two cell populations. In this study, we transiently eliminated the mitotic cell population by irradiating
glioblastoma cells, which allowed us to examine the extent
to which the MTA, MBZ, can radiosensitize these cells in
a cell population that is essentially made up of interphase
cells only. Our results show that in this system, the effect
of MBZ in interphase is responsible for the majority of the
radiosensitization effect caused by this MTA.
For a long time, MTAs have been believed to inhibit
tumor growth primarily by targeting mitotic cells, but this
hypothesis has come under considerable scrutiny.11,12,15,16
We examined the role of interphase microtubules by determining the effect of MBZ as a radiosensitizer, when present during
a time window in which mitosis is prevented by G2–M cell
cycle arrest. We showed that this regimen is better at radiosensitization of tumor cells than when MBZ is present before IR
administration, leading to an increase in the number of mitotic
cells, and is very similar to that caused by chronic treatment
with MBZ, strongly indicating that interphase microtubules are
indeed the targets of MBZ. In addition, the EC50 of MBZ for
radiosensitization is much lower than that for inducing mitotic
arrest, further supporting the notion that the radiosensitizing
effect of MBZ is independent of its effect on mitosis. We found
essentially the same results for VCR. Thus, most likely this
conclusion holds for a wide range of MTAs.
We also observed that MBZ, even when applied for only
6 hours, leads to a strong delay in the DDR. Thus, our results
strongly support the hypothesis that MTAs prolong DNA
damage repair by interfering with the trafficking of DDR
proteins from the cytosol to the nucleus.17
Interestingly, the EC50 for radiosensitization by MBZ
(35 nM) is very similar to that of cytoplasmic sequestration
of DDR proteins by MBZ (25 nM), which is much lower than
the EC50 of MBZ for the induction of mitotic arrest (184 nM),
further supporting the notion that MTAs radiosensitize by
blocking trafficking of DDR proteins to the nucleus. The low
EC50 of MBZ for the inhibition of DDR protein trafficking
is surprising, because it is also much lower than the EC50 for
microtubule depolymerization (132 nM) that we determined
recently.23 This EC50 largely reflects that of the depolymerization of interphase microtubules, as most of the cells are
in interphase.
Although the mechanistic basis for the relatively low EC50
of MBZ for the inhibition of DDR protein trafficking remains
to be determined, it will be of great interest to examine
OncoTargets and Therapy 2017:10
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whether our findings with MBZ extend to other MTAs. Our
observation that radiosensitization can be accomplished at
a concentration of MBZ that is significantly lower than the
concentration needed for cell killing on its own also has
important clinical implications, as it suggests the possibility
to utilize a dose of MBZ that minimizes toxicity. Importantly,
our results also have implications for the optimal timing
of administration of MTAs when used as radiosensitizers.
Indeed, we show that optimal radiosensitization is obtained
when inhibition of microtubule formation is achieved during
the post-IR DNA repair period.
This study also underlines the critical role of microtubulebased transport in the response to DNA damage. Thus, further
elucidation of these mechanisms may lead to the identification of novel therapeutic targets for radiosensitization.

Conclusion
We have shown that MBZ sensitizes cancer cells to IR in
a manner that is largely independent of the induction of
mitotic arrest by this microtubule inhibitor. We also provide
evidence that MBZ-induced radiosensitization is mediated by
inhibiting DDR protein accumulation into the nucleus. Thus,
this study strongly supports a critical role for DDR protein
trafficking in the response to radiation, suggesting that elements of the protein trafficking machinery can be mined for
additional radiosensitization targets.
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